P
Peter van Sluis
Researcher at University of Amsterdam
Publications - 5
Citations - 873
Peter van Sluis is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Neuroblastoma & Enhancer. The author has an hindex of 4, co-authored 5 publications receiving 599 citations.
Papers
More filters
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.
Journal ArticleDOI
Neuroblastoma is composed of two super-enhancer-associated differentiation states
Tim van Groningen,Jan Koster,Linda J. Valentijn,Danny A. Zwijnenburg,Nurdan Akogul,Nancy E. Hasselt,Marloes Broekmans,Franciska Haneveld,Natalia E Nowakowska,Johannes Bras,Carel J. M. van Noesel,Aldo Jongejan,Antoine H. C. van Kampen,Linda Koster,Frank Baas,Lianne van Dijk-Kerkhoven,Margriet Huizer-Smit,Maria C. Lecca,Alvin Chan,Arjan Lakeman,Piet Molenaar,Richard Volckmann,Ellen M. Westerhout,Mohamed Hamdi,Peter van Sluis,Marli E. Ebus,Marli E. Ebus,Jan J. Molenaar,Jan J. Molenaar,Godelieve A.M. Tytgat,Bart A. Westerman,Johan van Nes,Rogier Versteeg +32 more
TL;DR: It is shown that most neuroblastomas include two types of tumor cells with divergent gene expression profiles, and two super-enhancer-associated TF networks thus dominate epigenetic control of neuroblastoma and shape intratumoral heterogeneity.
Journal ArticleDOI
A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma.
Tim van Groningen,Nurdan Akogul,Ellen M. Westerhout,Alvin Chan,Nancy E. Hasselt,Danny A. Zwijnenburg,Marloes Broekmans,Peter Stroeken,Franciska Haneveld,Gerrit K. J. Hooijer,C. Dilara Savci-Heijink,Arjan Lakeman,Richard Volckmann,Peter van Sluis,Linda J. Valentijn,Jan Koster,Rogier Versteeg,Johan van Nes +17 more
TL;DR: This work unravels how a NOTCH3 intracellular domain reprogrammed the ADRN transcriptional landscape towards a MES state and elucidate a swift transdifferentiation between two semi-stable epigenetic cellular states.
Journal ArticleDOI
RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Thomas F. Eleveld,Linda Schild,Jan Koster,Danny A. Zwijnenburg,Lindy K. Alles,Marli E. Ebus,Richard Volckmann,Godelieve A. Tijtgat,Peter van Sluis,Rogier Versteeg,Jan J. Molenaar +10 more
TL;DR: This work identifies CIC as a powerful tumor suppressor affecting the RAS-MAPK pathway in neuroblastoma and reinforces the importance of mutation-driven activation of this pathway in cancer.
Posted ContentDOI
MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma
Thomas F. Eleveld,Lindy Vernooij,Linda Schild,Bianca Koopmans,Lindy K. Alles,Marli E. Ebus,Peter van Sluis,Huib N. Caron,Jan Koster,Rogier Versteeg,Emmy Dolman,Jan J. Molenaar +11 more
TL;DR: Results show that MEK inhibitors and specific Bcl2 family member inhibitors are a potent combination for RAS-MAPK mutated neuroblastoma tumors.